Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
Celcuity climbed by 661.96 percent in 2025, with the overall rally primarily fueled by strong results from the phase 3 clinical trial of its treatment candidate for breast cancer. In an updated report which was presented to the 2025 San Antonio Breast Cancer Symposium early last month, Celcuity Inc. (NASDAQ:CELC) said that its treatment candidate, gedatolisib, in combination with palbociclib and fulvestrant, saw patients' cancer stay under control for around 12.4 months, while those who took the gedatolisib and fulvestrant combination saw progression-free survival (PFS) for 10 months. The results represented a significant improvement from only 1.9 months in PFS for those who took the fulvestrant alone. Additional safety analyses were also performed, with mouth sore the only most common side effect observed. “We are very excited that patients reported nearly two years of delay in definitive deterioration of their well-being. This provides meaningful evidence of how well patients tole
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Wells Fargo Initiates Coverage On Celcuity Inc. (CELC) [Yahoo! Finance]Yahoo! Finance
- Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond [Seeking Alpha]Seeking Alpha
- How Investors Are Reacting To Celcuity (CELC) Gedatolisib's Phase 3 Breast Cancer Data And Safety Profile [Yahoo! Finance]Yahoo! Finance
- Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation [Yahoo! Finance]Yahoo! Finance
- Celcuity (NASDAQ:CELC) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.MarketBeat
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 1/16/26 - Form SCHEDULE
- 1/9/26 - Form 4
- 1/9/26 - Form S-3ASR
- CELC's page on the SEC website